Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Amling

Showing results (161-170 of 199) with videos related to

Pageof 20
Sort By:
Cancer Causes & Control : CCC|April 18, 2018
Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH databaseAdriana C Vidal, Lauren E Howard, Amanda de Hoedt, et al.
Cancer|November 15, 2018
Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?Adriana C Vidal, Lauren E Howard, Amanda De Hoedt, et al.
The Prostate|September 30, 2016
Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH DatabaseZachary S Zumsteg, Zinan Chen, Lauren E Howard, et al.
The Prostate|October 11, 2017
Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCHZachary S Zumsteg, Zinan Chen, Lauren E Howard, et al.
Journal of the National Cancer Institute|September 27, 2014
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancerLawrence Fong, Peter Carroll, Vivian Weinberg, et al.
Cancer|January 3, 2025
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancerPeris Castaneda, Paige K Kuhlmann, Jaruda Ithisuphalap, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2023
Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH CohortAndrei Sergeyev, Lin Gu, Amanda M De Hoedt, et al.
Cancer Medicine|March 8, 2024
Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCHLourdes Guerrios-Rivera, Jessica L Janes, Amanda M De Hoedt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2003
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomyChristopher L Amling, Robert H Riffenburgh, Leon Sun, et al.
Cancer|December 11, 2014
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?Zachary Klaassen, Abhay A Singh, Lauren E Howard, et al.
Pageof 20

Showing results (161-170 of 199) with videos related to

Sort By:
Pageof 20
Cancer Causes & Control : CCC|April 18, 2018
Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH databaseAdriana C Vidal, Lauren E Howard, Amanda de Hoedt, et al.
Cancer|November 15, 2018
Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?Adriana C Vidal, Lauren E Howard, Amanda De Hoedt, et al.
The Prostate|September 30, 2016
Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH DatabaseZachary S Zumsteg, Zinan Chen, Lauren E Howard, et al.
The Prostate|October 11, 2017
Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCHZachary S Zumsteg, Zinan Chen, Lauren E Howard, et al.
Journal of the National Cancer Institute|September 27, 2014
Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancerLawrence Fong, Peter Carroll, Vivian Weinberg, et al.
Cancer|January 3, 2025
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancerPeris Castaneda, Paige K Kuhlmann, Jaruda Ithisuphalap, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2023
Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH CohortAndrei Sergeyev, Lin Gu, Amanda M De Hoedt, et al.
Cancer Medicine|March 8, 2024
Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCHLourdes Guerrios-Rivera, Jessica L Janes, Amanda M De Hoedt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2003
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomyChristopher L Amling, Robert H Riffenburgh, Leon Sun, et al.
Cancer|December 11, 2014
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?Zachary Klaassen, Abhay A Singh, Lauren E Howard, et al.
Pageof 20